Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo

• DOI: 10.1016/j.tranon.2024.102073
• Publication Date: 2024-08-26T21:43:45Z
• Authors: Neil T Conlon; Sandra Roche; Amira F Mahdi; Alacoque Browne; Laura Breen; Johanna Gaubatz; Justine Meiller; Fiona O'Neill; Lorraine O'Driscoll; Mattia Cremona; Bryan T Hennessy; Lisa D Eli; John Crown; Denis M Collins
• Keywords: Neratinib

HER2-targeted therapies have revolutionised the treatment of HER2-positive breast cancer. However, de novo resistance or emergence acquired is a persistent clinical problem. Here we report that neratinib, an irreversible pan-HER inhibitor, in combination with multi-kinase inhibitor dasatinib, currently used to treat certain leukemias, has strong anti-proliferative effects against models cancer are innately resistant trastuzumab neratinib.